REGN vs. TEM: Regeneron Pharmaceuticals vs. Tempus AI Stock Comparison

Company Profile

Regeneron Pharmaceuticals (REGN) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Regeneron Pharmaceuticals (REGN) carries decades of public-market history since April 2, 1991, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the REGN side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Regeneron Pharmaceuticals (REGN) is defensive at 0.10 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Regeneron Pharmaceuticals (REGN) reports 14.95%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Regeneron Pharmaceuticals (REGN) reports 28.51%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Regeneron Pharmaceuticals (REGN) reports 40.46%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Regeneron Pharmaceuticals (REGN) at 0.99% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Regeneron Pharmaceuticals (REGN) at 3.35 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Regeneron Pharmaceuticals (REGN) at 0.08 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Regeneron Pharmaceuticals (REGN) trades at 19.99 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Regeneron Pharmaceuticals (REGN) at 2.71 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics